Literatur
- 1
Mellors J W, Munoz A, Giorgi J V. et al .
Plasma viral load and CD4+ lymphocytes
as prognostic markers of HIV-1 infection.
Annals of Internal
Medicine.
1997;
126
946-954
- 2
Cameron D W, Heath-Chiozzi M, Danner S. et al. The Advanced HIV Disease Ritonavir
Study Group .
Randomised
placebo-controlled trial of ritonavir in advanced HIV-1 disease.
Lancet.
1998;
351
543-549
- 3
Hammer S M, Squires K E, Hughes M D. et al. AIDS Clinical Trials Group 320 Study Team
.
A
controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts
of 200 per cubic millimeter or less.
N Engl J Med.
1997;
337
725-733
- 4
Palella F J, Delaney K M, Moorman A C. et al. HIV Outpatient Study Investigators .
Declining
morbidity and mortality among patients with advanced human immunodeficiency
virus infection.
N Engl J Med.
1998;
338
853-860
- 5
Egger M, May M, Chene G, Phillips A N, Ledergerber B, Dabis F, Costagliola D, D’Arminio
Monforte A, de
Wolf F, Reiss P, Lundgren J D, Justice A C, Staszewski S, Leport C, Hogg R S, Sabin C A,
Gill M J, Salzberger B, Sterne J A.
Prognosis
of HIV-1-infected patients starting highly active antiretroviral therapy:
a collaborative analysis of prospective studies.
Lancet.
2002;
360
119-29
- 6
Raboud J M, Montaner J S, Conway B. et al .
Suppression of plasma viral load below
20 copies/ml is required to achieve a long-term response
to therapy.
AIDS.
1998;
12
p1619-1624
- 7
Kempf D J, Rode R A, Xu Y. et al .
The duration of viral suppression during protease
inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1
RNA at the nadir.
AIDS.
1998;
12
F9-F14
- 8
Hirsch M S, Conway B, D’Aquila R T. et al. International AIDS Society - USA Panel
.
Antiretroviral
drug resistance testing in adults with HIV infection: implications
for clinical management.
JAMA.
1998;
279
p1984-1991
- 9
d’Arminio Monforte A, Testa L, Adorni F. et al .
Clinical outcome and predictive factors
of failure of highly active antiretroviral therapy in antiretroviral-experienced
patients in advanced stages of HIV-1 infection.
AIDS.
1998;
12
1631-1637
- 10
Volberding P A, Lagakos S W, Koch M A. et al. The AIDS Clinical Trials Group of
the National Institute of Allergy and Infectious Diseases .
Zidovudine
in asymptomatic human immunodeficiency virus infection. A controlled trial
in persons with fewer than 500 CD4-positive cells per cubic millimeter.
N
Engl J Med.
1990;
322
p941-949
- 11
Mulder J W, Cooper D A, Mathiesen L. et al. The European-Australian Collaborative
Group (Study 017) .
Zidovudine
twice daily in asymptomatic subjects with HIV infection and a high
risk of progression to AIDS: a randomized, double-blind placebo-controlled
study.
AIDS.
1994;
8
313-321
- 12
Volberding P A, Lagakos S W, Grimes J M. et al. AIDS Clinical Trials Group .
A comparison
of immediate with deferred zidovudine therapy for asymptomatic HIV-infected
adults with CD4 cell counts of 500 or more per cubic millimeter.
N
Engl J Med.
1995;
333
401-407
- 13
Concorde Coordinating Committee.
Concorde Coordinating Committee .
Concorde: MRC/ANRS
randomised double-blind controlled trial of immediate and deferred
zidovudine in symptom-free HIV infection.
Lancet.
1994;
343
871-881
- 14
De Kinloch-Loes S, Hirschel B J, Hoen B. et al .
A controlled trial of zidovudine in primary
human immunodeficiency virus infection.
N Engl J Med.
1995;
333
408-413
- 15
Lindbäck S, Vizzard J, Cooper D A, Gaines H.
Long-term prognosis following
Zidovudine monotherapy in primary human immunodeficiency virus type
1 infection.
JID.
1999;
179
1549-1552
- 16
Murphy R L, Brun S, Hicks C. et
al .
ABT-378/ritonavir plus stavudine and lamivudine
for the treatment of antiretroviral-naive adults with HIV-1 infection:
48-week results.
AIDS.
2001;
15
F1-9
- 17
Rockstroh J K, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fatkenheuer G, Oette M, Carls H,
Fenske S, Nadler M, Knechten H. German
Ritonavir/Indinavir Study Group .
Efficacy
and safety of twice daily first-line ritonavir/indinavir
plus double nucleoside combination therapy in HIV-infected individuals.
AIDS.
2000;
14
1181-1185
- 18
Staszewski S, Morales-Ramirez J, Tashima K T. et al .
Efavirenz plus zidovudine
and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine
and lamivudine in the treatment of HIV-1 infection in adults.
N
Engl J Med.
1999;
341
1865-1873
- 19 Staszewski S, Keiser P, Gathe J. et al .Comparison of antiviral response with abacavir/combivir
to indinavir/combivir in therapy-naive adults at 48 weeks
(CNA3005) (Abstract 505). 39th Interscience Conference
on Antimicrobial Agents and Chemotherapy. San Francisco, CA 1999
- 20 Ruane P, Parenti D, Hessenthaler S, Shepp D, Spragion D, Kauf T, Yau L, St. Clair M,
Goodwin D, Hernandez J. for the COL30336 Study Team .The
PI-sparing, compact, quad regimen of Combivir/Abacavir/efavirenz
(AOM/ABC/EFV) is potent and well tolerated in
naive subjects with high viral loads: 24-week data. Abstract # 221. 1st
IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires,
Argentina, July 8 - 11 2001
- 21
Back D J, Gibbons S E, Khoo S H, Merry C, Barry M G, Mulcahy F M.
Therapeutic
drug monitoring of antiretrovirals: ready for the clinic?.
J
Int Assoc Physicians AIDS Care.
2000;
6
34-37
- 22 Piscitelli S, Bechtel C, Sadler B, Falloon J. The addition of a second
protease inhibitor eliminated amprenavir-efavirenz interactions
and increased amprenavir concentrations (Abstract 90). 7th
Conference on Retroviruses and Opportunistic Infections. San Francisco,
CA 2000
- 23 Saah A J, Winchell G, Seniuk M, Deutsch P. Multiple-dose pharmacokinetics
and tolerability of indinavir-ritonavir combinations in healthy
volunteers (Abstract 136). 6th Conference on Retroviruses
and Opportunistic Infections. Chicago 1999
- 24
Cameron D W, Japour A J, Xu Y. et al .
Ritonavir and saquinavir combination therapy
for the treatment of HIV infection.
AIDS.
1999;
13
213-224
- 25
Larder B A, Darby G, Richman D D.
HIV
with reduced sensitivity to zidovudine (AZT) isolated during prolonged
therapy.
Science.
1989;
243
1731-1734
- 26
D’Aquila R T, Johnson V A, Welles S L. et al .
Zidovudine resistance
and HIV-1 disease progression during antiretroviral therapy.
Ann
Intern Med.
1995;
122
401-408
- 27
DeGruttola V, Dix L, A’Aquila R. et al .
The relationship between baseline HIV drug
resistance and response to antiretroviral therapy: re-analysis of retrospective
and prospective studies using a standardized data analysis plan.
Antiviral
Therapy.
2000;
5
43-50
- 28
Durant J, Clevenbergh F, Halfon F. et al .
Drug-resistance genotyping in HIV-l therapy:
the VIRADAPT randomised controlled trial.
Lancet.
1999;
353
2195-2199
- 29
Baxter J D, Mayers D L, Wentworth D N. et al. CPCRA 046 Study Team for the Terry Beirn
Community Programs for Clinical Research on AIDS .
A randomized
study of antiretroviral management based on plasma genotypic antiretroviral
resistance testing in patients failing therapy.
AIDS.
2000;
14
F83-93
- 30
Cingolani A, Antinori A, Rizzo M G. et al .
Usefulness of monitoring HIV drug resistance
and adherence in individuals failing highly active antiretroviral
therapy: a randomized study (ARGENTA).
AIDS.
2002;
16
369-379
- 31
Tural C, Ruiz L, Holtzer C. et al .
Clinical utility of HIV-1 genotyping and
expert advice: the Havana trial.
AIDS.
2002;
16
209-218
- 32
Cohen C J, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W,
Hertogs K, Ames M, Rinehart A R, Graham N M. VIRA3001 Study
Team .
A randomized trial assessing the impact of phenotypic
resistance testing on antiretroviral therapy.
AIDS.
2002;
16
579-588
- 33
Meynard J L, Vray M, Morand-Joubert L. et al .
Impact of treatment guided by phenotypic
or genotypic resistance tests on the response to antiretroviral
therapy: a randomized trial (NARVAL, ANRS 088).
Antiviral
Therapy.
2000;
5
67-68
(Suppl 3)
- 34
The EuroGuidelines Group
for HIV Resistance .
Clinical and laboratory guidelines
for the use of HIV-1 drug resistance testing as part of treatment
management: recommendations for the European setting.
AIDS.
2001;
15
309-320
- 35
Carpenter C C, Cooper D A, Fischl M A. et al .
Antiretroviral therapy in
adults: updated recommendations of the International AIDS Society-USA
Panel.
JAMA.
2000;
283
381-390
- 36
Duwe S, Brunn M, Altmann D. et
al .
Frequency of genotypic and phenotypic drug-resistant
HIV-1 among therapy-naive patients of the German Seroconverter Study.
J
Acquir Immune Defic Syndr.
2001;
26
266-273
- 37
Acosta E P, Henry K, Baken L, Page L M, Fletcher C V.
Indinavir concentrations and antiviral effect.
Pharmacotherapy.
1999;
19
708-712
- 38 Burger D M, Hoetelmans R MW, Mulder J W. et al .Low plasma levels
of indinavir (IDV) are highly predictive of virological treatment
failure in patients using IDV-containing triple therapy (Abstr.
828). 12th World AIDS Conference, Geneva, June 28-July
3 1998
- 39 Acosta E P. The
promise of therapeutic drug monitoring in HIV infection. (http://www.medscape.com/medscape/HIV/journal/1999/v05.n04/mha0803/mha0803.acos/mha0803.acos-01.html.)
(See NAPS document no. 05 584 for 5 pages, c/o
Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY
11 552.) August 1999
- 40 Piscitelli S C. The limited value of therapeutic drug monitoring
in HIV infection. (http://www.medscape.com/medscape/HIV/journal/1999/v05.n04/mha0803/mha0803.pisc/mha0803.pisc-01.html.)
(See NAPS document no. 05 584 for 4 pages, c/o
Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY
11 552.) August 1999
- 41
Niehues T, Wintergerst U, Funk M, Notheis G. et al .
Empfehlungen
zur antiretroviralen Therapie bei HIV-infizierten Kindern.
Monatsschr
Kinderheilkd.
2001;
149
1372-1382
- 42 Deutsch-Österreichische
Empfehlungen zur HIV-Therapie in der Schwangerschaft. Aktualisierung
Mai 2001. http://www.rki.de/INFEKT/AIDS_STD/BR_LINIE/BR_LINIE.HTM 2001
- 43 Postexpositionelle Prophylaxe
nach HIV-Exposition. Deutsch-Österreichische Empfehlungen. Aktualisierung
Mai 2002. http://www.rki.de/INFEKT/AIDS_STD/EXPO/HIV.HTM 2002
Prof. Dr. N. H. Brockmeyer
Klinik für Dermatologie und Allergologie der
Ruhr Universität
Gudrunstr. 56
44791
Bochum
Telefon: 0234-509 3471
Fax: 0234-509 3472
